Hims & Hers slips ahead of White House meeting on peptide policy

Hims & Hers Health

23/10/2026 15:44

** Shares of telehealth firm Hims & Hers Health HIMS.N fall 4.5% to $27.82, ahead of a White House review meeting on peptide compounding policies today
** The meeting, requested by Hims & Hers Health, is set for 2:00 pm ET on Oct 23, as per the Office of Information and Regulatory Affairs' website 
** Last week, the US FDA submitted a proposed policy change to the White House for review that could make it easier for pharmacies to compound certain peptides
** HIMS previously said it plans to offer peptides if regulations permit
** Earlier this week, US Health Secretary Robert F. Kennedy Jr. said the administration aims to expand access to peptides by creating a regulated marketplace
** As of last close, stock down ~14% YTD

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))